www.tickerreport.com ·
Arrowhead Pharmaceuticals Nasdaqarwr Hits New 12 Month High Whats Next
Topic context
This topic has been covered 407751 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe news reports a stock price milestone for Arrowhead Pharmaceuticals, a biotech firm focused on RNAi therapeutics. The price increase follows an earnings beat and analyst upgrades. However, there is no concrete commercial mechanism such as a new drug approval, partnership, or supply chain event. The impact is company-specific and does not indicate sector-wide changes. Insider selling suggests some caution. Overall, the commercial mechanism is weak.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Arrowhead Pharmaceuticals (ARWR) hit a 52-week high of $77.2350 on May 7, 2026.
- Q2 2026 EPS was ($0.93), beating consensus estimate of ($1.11).
- Revenue was $73.74 million.
- B. Riley Financial raised price target from $61 to $101.
- CFO Daniel Joseph Apel sold 13,095 shares; insider James C. Hamilton sold 10,000 shares.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
economictimes.indiatimes.com
The Rs 3 Relief That Wasnt Why Investors Are Dumping Oil Stocks After Long Awaited Petrol Diesel Price Hike
livemint.com